NASDAQ$ETON
Eton Pharmaceuticals Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Eton Pharmaceuticals reported financial results, showing significant growth in product sales and royalties.
Eton Pharmaceuticals reported a 315% increase in product sales and royalties compared to the prior year, driven by growth in ALKINDI SPRINKLE and Carglumic Acid. The company also acquired Betaine Anhydrous and received FDA approval for Zonisade™.
- Reported seventh straight quarter of sequential growth in product sales and royalty revenue.
- Total revenue reached $3.2 million, a 315% increase year-over-year.
- ALKINDI SPRINKLE sales grew by 183% compared to the prior year.
- Acquired Betaine Anhydrous, a third FDA-approved rare disease product.
Headline financials
Revenue & EPS history
Eton · Revenue · Quarterly
$3.22M
Revenue by segment
Eton · $3.2M total across 1 segment · Q3 2022
- Product Sales and Royalties$3.2M—100.0%
Forward guidance
Eton expects Betaine Anhydrous to be accretive to earnings in 2023 and anticipates additional product launches in 2023 and 2024.
Tailwinds
- Betaine Anhydrous shares the same prescriber base as Carglumic Acid.
- Betaine Anhydrous expected to be accretive to Eton’s earnings in 2023.
- Potential for additional product launches in 2023 and 2024.
- Zonisade was launched in October, triggering a $5 million milestone payment.
- Carglumic Acid remains on track to reach its goal of capturing 25-35% market share.
Headwinds
- No specific negative forward-looking statements were found in the provided text.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+0.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+1.9%
Avg return
30 days after
48%
15 / 31 earnings
Positive
+36.0%
Q2 2023
Best reaction
-14.1%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.0% | +6.7% | — | |
| Q4 2025 | +7.5% | +14.8% | +20.6% | |
| Q3 2025 | -11.4% | -8.8% | -15.0% | |
| Q2 2025 | +12.5% | +12.2% | +15.8% | |
| Q1 2025 | +0.4% | +14.6% | -16.2% | |
| Q4 2024 | -4.0% | -7.0% | -6.2% | |
| Q3 2024 | +9.2% | +3.2% | +25.2% | |
| Q2 2024 | +6.6% | +8.0% | +31.5% | |
| Q1 2024 | -7.8% | -2.4% | -3.0% | |
| Q4 2023 | -14.1% | -21.0% | -23.7% | |
| Q3 2023 | -13.7% | -16.6% | -19.1% | |
| Q2 2023 | +36.0% | +79.5% | +83.7% | |
| Q1 2023 | +2.8% | +2.6% | +10.3% | |
| Q4 2022 | +2.6% | +7.1% | -7.4% | |
| Q3 2022 | +18.5% | +20.9% | +22.8% | |
| Q2 2022 | -1.0% | -19.4% | -22.8% | |
| Q1 2022 | +1.3% | +6.5% | -4.9% | |
| Q4 2021 | +6.1% | +8.7% | -1.5% | |
| Q3 2021 | -3.4% | -9.2% | -20.7% | |
| Q2 2021 | -5.0% | -0.2% | +12.7% | |
| Q1 2021 | +5.2% | +7.5% | -13.4% | |
| Q4 2020 | -0.7% | -1.1% | +5.9% | |
| Q3 2020 | -1.5% | +2.9% | +19.9% | |
| Q2 2020 | -2.2% | +4.4% | +12.4% | |
| Q1 2020 | -9.2% | -10.3% | -1.1% | |
| Q4 2019 | -8.4% | -21.9% | -39.8% | |
| Q3 2019 | +1.9% | +2.3% | +9.2% | |
| Q2 2019 | +1.6% | -1.8% | -14.2% | |
| Q1 2019 | +3.2% | +12.2% | +5.9% | |
| Q4 2018 | -2.3% | +2.6% | -5.8% | |
| Q3 2018 | -8.1% | -4.8% | -3.2% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro